Premium
Sodium Alginate as a Novel Therapeutic Option in Experimental Colitis
Author(s) -
Mirshafiey A.,
Khodadadi A.,
Rehm B. H.,
Khorramizadeh M. R.,
Eslami M. B.,
Razavi A.,
Saadat F.
Publication year - 2005
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2005.01571.x
Subject(s) - colitis , sodium alginate , medicine , intensive care medicine , gastroenterology , chemistry , sodium , organic chemistry
The potential therapeutic effect of low‐viscosity sodium alginate (LVA) was studied in a rat model of acute colitis induced by intracolonic administration of acetic acid. This experimental model produced a significant ulcerative colitis. Induction of colitis also significantly enhanced the serum and colonic mucosal cytokine (IL‐6 and TNF‐α) and eicosanoid (LTB4 and PGE2) levels, which paralleled with the severity of colitis. LVA solution was administered orally as drinking water at concentration of 0.5% (W/V) for 1 week. The tolerability and inhibitory effect of LVA on matrix metalloproteinase‐2 (MMP‐2) were tested using WEHI‐164 cell line and zymography method. The results showed that LVA therapy is able to significantly reduce colonic damage score, histological lesion, serum and colonic mucosal IL‐6, TNF‐α, LTB4 and PGE2 levels in treated group compared with nontreated controls. Moreover, in vitro examinations revealed that treatment with LVA could diminish MMP‐2 activity. It is concluded that LVA is able to suppress acetic acid‐induced colitis in rats. Some of the action of LVA may be associated with its inhibitory effects on cytokine and eicosanoid production and MMP‐2 activity. Our data suggest that LVA could potentially be a novel therapeutic option for inflammatory bowel disease.